Skip to main content

$11.22 -0.22 (-1.92%)

High

$11.49

Low

$11.20

Trades

4,718

Turnover

$7,499,551

Volume

664,557
30 June 2023 at 4:12pm
Register to track TLX and receive email alerts.

FDA New Drug Application for TLX591-CDx Proceeds to Review

StockBot

416,823 posts

TLX released this announcement to the ASX on 9 December 2020, 8:21. The announcement is marked as price sensitive, and is 2 page(s) in length and 222.21kb in size.

You can view all announcements from TLX and see how they appear on a price chart on the announcements page.

At the date of this announcement, TLX was 0.040% short sold according to ASIC data. It was ranked the 469th most shorted stock on the ASX. It is now ranked as the 48th most shorted stock on the ASX with 4.944% of total shares short sold as of the latest reported data (19 June 2025).

Other Recent Announcements from TLX
Cleansing Notice 28 June 2023, 8:23
Application for quotation of securities - TLX 28 June 2023, 8:23
Proposed issue of securities - TLX 21 June 2023, 18:12
FDA New Drug Application for TLX591-CDx Proceeds to Review 9 December 2020, 8:21
TGA Priority Review Granted for Prostate Cancer Imaging 7 December 2020, 10:39
Overview of ProstACT Phase III Study - Investor supplement 3 December 2020, 8:25
ProstACT Phase III Study Clinical Development Update 3 December 2020, 8:25
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track TLX and receive email alerts.